PepGen Inc

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Cambridge, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

PepGen, Inc. (PEPG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's Why

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at SVB Securities' Global Biopharma Virtual Conference on Thursday, February 16th 2023, at 10:40 A.M. EST.

PepGen to Participate in the SVB Securities Global Biopharma Conference

PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going

- PGN-EDODM1 was well-tolerated in acute GLP studies in rodents and non-human primates (NHPs) at clinically relevant doses-

PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

The consensus price target hints at a 50.4% upside potential for PepGen, Inc. (PEPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High?

What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing'

The average of price targets set by Wall Street analysts indicates a potential upside of 68.1% in PepGen, Inc. (PEPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know

- In non-human primates (NHPs), high levels of exon 53 skipping were observed after a single dose of PGN-EDO53 – almost 7-times higher than those observed for a comparator peptide-phosphorodiamidate morpholino oligonucleotide (PPMO) conjugate molecule used as a positive control

PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent corporate developments.

PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at Stifel's 2022 Annual Healthcare Conference in New York, New York on November 15th, 2022, at 9:45 A.M. ET.

PepGen to Participate in the Stifel 2022 Healthcare Conference

BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced the presentation of data from its Duchenne muscular dystrophy program. The data are featured in a poster at the 27th International Hybrid Annual Congress of the World Muscle Society taking place in Halifax, Nova Scotia, Canada from October 11-15, 2022.

PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress

- PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 skipping approaches -

PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Habib Joseph Dable to its Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma, and brings nearly three decades of experience working with emerging biotech and big pharma companies.

PepGen Appoints Habib Dable to Board of Directors

Hanover Bancorp Inc/NY

ProFrac Holding Corp

Initial public offerings (IPOs) are often the most common route companies use to hit the public markets and raise money

3 IPO stocks to watch in September: PEPG, PFHC, HNVR

BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2022.

PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Caroline Godfrey, Ph.D., one of PepGen's scientific co-founders, to its Scientific Advisory Board. In connection with this appointment, Dr. Godfrey leaves her position as Senior Vice President of Discovery at PepGen.

PepGen Appoints Caroline Godfrey, Ph.D. to the Company's Scientific Advisory Board

Belite Bio Inc

HilleVax Inc

Takeda Pharmaceutical

SPDR S&P Biotech ETF

No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerings have sunk to a 10-year low, according to a report from Evaluate.

Biotech Public Offerings at 10-Year Low

BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2022.

PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Bausch + Lomb Corp

It's hard to know what to buy and what to sell with market conditions the way they are but it looks like a good time to start nibbling on these two recent IPOs. Bausch + Lomb (NYSE: BLCO) and PepGen (NASDAQ: PEPG) both IPOd in 2022 and have seen their shares plummet in the wake of the offering, not because they are poor companies or bad investments but simply because the market conditions changed.

It's Time To Nibble On These Two Recent IPOs

Mastercard

Andreas Halvorsen (Trades, Portfolio), founding partner and chief investment officer of Viking Global Investors LP, disclosed in a regulatory SEC 13G filing that his firm entered positions in PepGen Inc. ( PEPG , Financial) last week. The firm also revealed in a quarterly 13F holdings report that its top trades during the first quarter included a new holding in Mastercard Inc. ( MA , Financial), a reduction to its stake in Glingko Bioworks Holdings Inc. ( DNA , Financial) and the closure of its positions in Humana Inc. ( HUM , Financial) and Twilio Inc. ( TWLO , Financial).

Andreas Halvorsen's Firm Packs Into PepGen and Mastercard

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of its initial public offering. The offering consists of 9,000,000 shares of common stock at an initial public offering price of $12.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by PepGen, are expected to be $108.0 million. In addition, PepGen has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by PepGen.

PepGen Announces Pricing of Initial Public Offering

News for PepGen Inc Stock (PEPG)